ACS Medicinal Chemistry Letters
Page 6 of 7
(2) Rabinovich, R. N.; Drakeley, C.; Djimde, A. A.; Hall, B. F.; Hay,
against a resistance-compromised target. Proc. Natl. Acad. Sci.
U.S.A. 2012, 109, 16823-16828.
S. I.; Hemingway, J.; Kaslow, D. C.; Noor, A.; Okumu, F.; Steketee, R.;
Tanner, M.; Wells, T. N. C.; Whittaker, M. A.; Winzeler, E. A.; Wirth,
D. F.; Whitfield, K.; Alonso, P. L. malERA: An updated research
agenda for malaria elimination and eradication. PLoS Med. 2017,
14, e1002456.
(3) Okombo, J.; Chibale, K. Recent updates in the discovery and
development of novel antimalarial drug candidates. Med. Chem.
Commun. 2018, 9, 437-453.
1
2
3
4
5
6
7
8
(16) Yuvaniyama, J.; Chitnumsub, P.; Kamchonwongpaisan, S.;
Vanichtanankul, J.; Sirawaraporn, W.; Taylor, P.; Walkinshaw, M. D.;
Yuthavong, Y. Insights into antifolate resistance from malarial
DHFR-TS structures. Nat. Struct. Biol. 2003, 10, 357-365.
(17) Kongsaeree, P.; Khongsuk, P.; Leartsakulpanich, U.;
Chitnumsub, P.; Tarnchompoo, B.; Walkinshaw, M. D.; Yuthavong,
Y. Crystal structure of dihydrofolate reductase from Plasmodium
vivax: pyrimethamine displacement linked with mutation-induced
resistance. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 13046-13051.
(18) Canfield, C. J.; Milhous, W. K.; Ager, A. L.; Rossan, R. N.;
Sweeney, T. R.; Lewis, N. J.; Jacobus, D. P. PS-15: a potent, orally
active antimalarial from a new class of folic acid antagonists. Am. J.
Trop. Med. Hyg. 1993, 49, 121-126.
(19) Yuthavong, Y.; Vilaivan, T.; Kamchonwongpaisan, S.;
Tarnchompoo, B.; Thongpanchang, C.; Chitnumsub, P.;
Yuvaniyama, J.; Matthews, D.; Charman, W.; Charman, S.; Vivas, L.;
Katiyar, S. B. Antimalarial Compounds with Flexible Side-Chains.
U.S. Patent 8,503,491. September 10, 2013.
(20) Ferlan, J. T.; Mookherjee, S.; Okezie, I. N.; Fulgence, L.; Sibley,
C. H. Mutagenesis of dihydrofolate reductase from Plasmodium
falciparum: analysis in Saccharomyces cerevisiae of triple mutant
alleles resistant to pyrimethamine or WR99210. Mol. Biochem.
Parasitol. 2001, 113, 139-150.
(21) Chusacultanachai, S.; Thiensathit, P.; Tarnchompoo, B.;
Sirawaraporn, W.; Yuthavong, Y. Novel antifolate resistant
mutations of Plasmodium falciparum dihydrofolate reductase
selected in Escherichia coli. Mol. Biochem. Parasitol. 2002, 120, 61-
72.
(22) Japrung, D.; Leartsakulpanich, U.; Chusacultanachai, S.;
Yuthavong, Y. Conflicting requirements of Plasmodium falciparum
dihydrofolate reductase mutations conferring resistance to
pyrimethamine-WR99210 combination. Antimicrob. Agents
Chemother. 2007, 51, 4356-4360.
(23) Tarnchompoo, B.; Sirichaiwat, C.; Phupong, W.; Intaraudom,
C.; Sirawaraporn, W.; Kamchonwongpaisan, S.; Vanichtanankul, J.;
Thebtaranonth, Y.; Yuthavong, Y. Development of 2,4-
diaminopyrimidines as antimalarials based on inhibition of the
S108N and C59R+S108N mutants of dihydrofolate reductase from
pyrimethamine-resistant Plasmodium falciparum. J. Med. Chem.
2002, 45, 1244-1252.
(24) Holsworth, D. D.; Jeremy, M. S.; Edmunds, J.; He, W.; Place,
S.; Maiti, S. An Expeditious Synthesis of 6-Alkyl-5-(4′-amino-
phenyl)-pyrimidine-2,4-diamines. Synth. Commun. 2003, 33, 3467-
3475.
(4) Hooft van Huijsduijnen, R.; Wells, T. N. The antimalarial
pipeline. Curr. Opin. Pharmacol. 2018, 42, 1-6.
9
(5) Imwong, M.; Suwannasin, K.; Kunasol, C.; Sutawong, K.;
Mayxay, M.; Rekol, H.; Smithuis, F. M.; Hlaing, T. M.; Tun, K. M.; van
der Pluijm, R. W.; Tripura, R.; Miotto, O.; Menard, D.; Dhorda, M.;
Day, N. P. J.; White, N. J.; Dondorp, A. M. The spread of artemisinin-
resistant Plasmodium falciparum in the Greater Mekong subregion:
a molecular epidemiology observational study. Lancet Infect. Dis.
2017, 17, 491-497.
(6) Straimer, J.; Gnadig, N. F.; Witkowski, B.; Amaratunga, C.;
Duru, V.; Ramadani, A. P.; Dacheux, M.; Khim, N.; Zhang, L.; Lam, S.;
Gregory, P. D.; Urnov, F. D.; Mercereau-Puijalon, O.; Benoit-Vical, F.;
Fairhurst, R. M.; Menard, D.; Fidock, D. A. Drug resistance. K13-
propeller mutations confer artemisinin resistance in Plasmodium
falciparum clinical isolates. Science 2015, 347, 428-431.
(7) The malERA Refresh Consultative Panel on Insecticide and
Drug Resistance. malERA: An updated research agenda for
insecticide and drug resistance in malaria elimination and
eradication. PLoS Med. 2017, 14, e1002450.
(8) Woodrow, C. J.; Dahlstrom, S.; Cooksey, R.; Flegg, J. A.; Le
Nagard, H.; Mentre, F.; Murillo, C.; Menard, D.; Nosten, F.; Sriprawat,
K.; Musset, L.; Quashie, N. B.; Lim, P.; Fairhurst, R. M.; Nsobya, S. L.;
Sinou, V.; Noedl, H.; Pradines, B.; Johnson, J. D.; Guerin, P. J.; Sibley,
C. H.; Le Bras, J. High-throughput analysis of antimalarial
susceptibility data by the WorldWide Antimalarial Resistance
Network (WWARN) in vitro analysis and reporting tool.
Antimicrob. Agents Chemother. 2013, 57, 3121-3130.
(9) Corey, V. C.; Lukens, A. K.; Istvan, E. S.; Lee, M. C.; Franco, V.;
Magistrado, P.; Coburn-Flynn, O.; Sakata-Kato, T.; Fuchs, O.; Gnadig,
N. F.; Goldgof, G.; Linares, M.; Gomez-Lorenzo, M. G.; De Cozar, C.;
Lafuente-Monasterio, M. J.; Prats, S.; Meister, S.; Tanaseichuk, O.;
Wree, M.; Zhou, Y.; Willis, P. A.; Gamo, F. J.; Goldberg, D. E.; Fidock,
D. A.; Wirth, D. F.; Winzeler, E. A., A broad analysis of resistance
development in the malaria parasite. Nat. Commun. published
online June 15, 2016; DOI: 10.1038/ncomms11901.
(10) Gregson, A.; Plowe, C. V. Mechanisms of resistance of
malaria parasites to antifolates. Pharmacol. Rev. 2005, 57, 117-
145.
(11) Venkatesan, M.; Alifrangis, M.; Roper, C.; Plowe, C. V.
Monitoring antifolate resistance in intermittent preventive
therapy for malaria. Trends Parasitol. 2013, 29, 497-504.
(12) Nzila, A. The past, present and future of antifolates in the
treatment of Plasmodium falciparum infection. J. Antimicrob.
Chemother. 2006, 57, 1043-1054.
(13) Yuthavong, Y.; Kamchonwongpaisan, S.; Leartsakulpanich,
U.; Chitnumsub, P. Folate metabolism as a source of molecular
targets for antimalarials. Future Microbiol. 2006, 1, 113-125.
(14) Yuthavong, Y.; Yuvaniyama, J.; Chitnumsub, P.;
Vanichtanankul, J.; Chusacultanachai, S.; Tarnchompoo, B.;
Vilaivan, T.; Kamchonwongpaisan, S. Malarial (Plasmodium
falciparum) dihydrofolate reductase-thymidylate synthase:
structural basis for antifolate resistance and development of
effective inhibitors. Parasitology 2005, 130, 249-259.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(25) Kamchonwongpaisan, S.; Quarrell, R.; Charoensetakul, N.;
Ponsinet, R.; Vilaivan, T.; Vanichtanankul, J.; Tarnchompoo, B.;
Sirawaraporn, W.; Lowe, G.; Yuthavong, Y. Inhibitors of multiple
mutants of Plasmodium falciparum dihydrofolate reductase and
their antimalarial activities. J. Med. Chem. 2004, 47, 673-680.
(26) Kamchonwongpaisan, S.; Vanichtanankul, J.; Tarnchompoo,
B.; Yuvaniyama, J.; Taweechai, S.; Yuthavong, Y. Stoichiometric
selection of tight-binding inhibitors by wild-type and mutant forms
of malarial (Plasmodium falciparum) dihydrofolate reductase. Anal.
Chem. 2005, 77, 1222-1227.
(27) Heinberg, A.; Kirkman, L. The molecular basis of antifolate
resistance in Plasmodium falciparum: looking beyond point
mutations. Ann. N. Y. Acad. Sci. 2015, 1342, 10-18.
(15) Yuthavong, Y.; Tarnchompoo, B.; Vilaivan, T.; Chitnumsub,
P.; Kamchonwongpaisan, S.; Charman, S. A.; McLennan, D. N.;
White, K. L.; Vivas, L.; Bongard, E.; Thongphanchang, C.; Taweechai,
S.; Vanichtanankul, J.; Rattanajak, R.; Arwon, U.; Fantauzzi, P.;
Yuvaniyama, J.; Charman, W. N.; Matthews, D. Malarial
dihydrofolate reductase as a paradigm for drug development
ACS Paragon Plus Environment